These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 36803843)

  • 1. Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis.
    Miyachi K; Iwamoto T; Kojima S; Ida T; Suzuki J; Yamamoto T; Mimura N; Sugiyama T; Tanaka S; Furuta S; Ikeda K; Suzuki K; Niewold TB; Nakajima H
    Arthritis Res Ther; 2023 Feb; 25(1):26. PubMed ID: 36803843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new 2019-EULAR/ACR classification criteria specific domains at diagnosis can predict damage accrual in 670 childhood-onset systemic lupus erythematosus patients.
    Pitta AC; Silva CA; Insfrán CE; Pasoto SG; Trindade VC; Novak GV; Sakamoto AP; Terreri MT; Pereira RM; Magalhães CS; Fonseca AR; Islabão AG; Assad AP; Buscatti IM; Elias AM; Piotto DP; Ferriani VP; Carvalho LM; Rabelo Junior CN; Marini R; Sztajnbok FR; Sacchetti SB; Bica BE; Moraes AJ; Robazzi TC; Lotufo S; Cavalcanti AS; Naka EN; Carneiro-Sampaio M; Bonfá E; Aikawa NE;
    Lupus; 2021 Dec; 30(14):2286-2291. PubMed ID: 34689652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus.
    Kandane-Rathnayake R; Kent JR; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra SA; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Hoi A; Nikpour M; Morand E
    Lupus; 2019 Dec; 28(14):1669-1677. PubMed ID: 31718467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus.
    Oke V; Gunnarsson I; Dorschner J; Eketjäll S; Zickert A; Niewold TB; Svenungsson E
    Arthritis Res Ther; 2019 Apr; 21(1):107. PubMed ID: 31036046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian populations.
    Joo YB; Bae SC
    Int J Rheum Dis; 2015 Feb; 18(2):117-28. PubMed ID: 25524656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
    Wirestam L; Enocsson H; Skogh T; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
    J Rheumatol; 2019 May; 46(5):492-500. PubMed ID: 30647177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature.
    Arnaud L; Furie R; Morand EF; Aringer M; Peschken C; Desta B; Rapsomaniki E; Hedberg J; Knagenhjelm J; Seo C; Grünfeld Eén T; Sorrentino A; Tummala R; Stirnadel-Farrant HA; Ding B
    Lupus Sci Med; 2023 Dec; 10(2):. PubMed ID: 38123459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
    Mende R; Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Lin E; Chang J; Hoi AY; Morand EF; Harris J; Lang T
    Front Immunol; 2018; 9():1250. PubMed ID: 29930551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of damage accrual in systemic lupus erythematosus: a longitudinal observational study with focus on neuropsychological factors and anti-neuronal antibodies.
    Mimica M; Barra I; Ormeño R; Flores P; Calderón J; Padilla O; Bravo-Zehnder M; González A; Massardo L
    Clin Rheumatol; 2019 Nov; 38(11):3129-3137. PubMed ID: 31367942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus.
    Insfrán CE; Aikawa NE; Pasoto SG; Filho DMN; Formiga FFC; Pitta AC; Borba EF; Ribeiro CT; Silva CA; Bonfa E
    Clin Rheumatol; 2022 Apr; 41(4):1079-1085. PubMed ID: 34782939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus.
    Mok CC; Chung YK; Lee C; Ho LY; To CH
    Lupus; 2023 Mar; 32(3):424-430. PubMed ID: 36651432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients.
    Chanprapaph K; Tubtieng I; Pratumchat N; Thadanipon K; Rattanakaemakorn P; Suchonwanit P
    Lupus; 2021 Apr; 30(5):785-794. PubMed ID: 33554715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus.
    Matsuoka N; Fujita Y; Temmoku J; Furuya MY; Asano T; Sato S; Matsumoto H; Kobayashi H; Watanabe H; Suzuki E; Kozuru H; Yastuhashi H; Migita K
    PLoS One; 2020; 15(1):e0227069. PubMed ID: 31986153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study.
    Apostolopoulos D; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra S; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand E;
    Lancet Rheumatol; 2020 Jan; 2(1):e24-e30. PubMed ID: 38258272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.
    Na Nakorn K; Piyaphanee N; Sukharomana M; Pinpatanapong R; Charuvanij S
    Clin Rheumatol; 2023 Jun; 42(6):1655-1664. PubMed ID: 36780064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity.
    Wu Q; Yang Q; Lourenco E; Sun H; Zhang Y
    Arthritis Res Ther; 2011 Jun; 13(3):R88. PubMed ID: 21679442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.
    Munroe ME; Lu R; Zhao YD; Fife DA; Robertson JM; Guthridge JM; Niewold TB; Tsokos GC; Keith MP; Harley JB; James JA
    Ann Rheum Dis; 2016 Nov; 75(11):2014-2021. PubMed ID: 27088255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.